{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29.8","upperLimit":"55.7","value":"42.5"},{"groupId":"OG001","lowerLimit":"20.9","upperLimit":"45.3","value":"32.5"}]}],"title":"Grades II-IV acute GVHD"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.7","upperLimit":"28.5","value":"17.5"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"0","value":"0"}]}],"title":"Grades III-IV acute GVHD"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Any skin, gastrointestinal or liver abnormalities fulfilling the BMT CTN Manual of Operations (2013) criteria of grades II-IV acute GVHD. A cumulative incidence will be computed along with a 90% CI.\n\nAny skin, gastrointestinal or liver abnormalities fulfilling the BMT CTN Manual of Operations (2013) criteria of grades III-IV acute GVHD. A cumulative incidence will be computed along with a 90% CI.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received one of three regimens: cyclophosphamide and total body irradiation; busulfan and cyclophosphamide; or fludarabine and busulfan","id":"OG000","title":"Myeloablative Conditioning (MAC)"},{"description":"Participants received one of two regimens: fludarabine, cyclophosphamide, and low-dose total body irradiation","id":"OG001","title":"Reduced Intensity Conditioning (RIC)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"100 days post-transplant","title":"Cumulative Incidence of Acute GVHD","type":"SECONDARY","unitOfMeasure":"percentage of participants"}